Pfirrmann, M ; Hoffmann, V ; Lauseker, M. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872-84..
,
2015
Pfirrmann, M ; Hehlmann, R ; Lauseker, M. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352(9134):1087-92..
,
2014
Lauseker, M ; Hehlmann, R ; Pfirrmann, M Van Houwelingen H, Dynamic Prediction by Landmarking in Event History Analysis. Scand J Stat. 2007;34 (1): 70-85..
,
2013
Pfirrmann, M ; Lauseker, M ; Hasford, J Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125(7):605-13..
,
2011
Pfirrmann, M ; Waibel, F ; Lauseker, M... Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998;90:850-8..
,
2008
